Perfusion MRI as a diagnostic biomarker for differentiating glioma from brain metastasis: a systematic review and meta-analysis
- 34 Downloads
Differentiation of glioma from brain metastasis is clinically crucial because it affects the clinical outcome of patients and alters patient management. Here, we present a systematic review and meta-analysis of the currently available data on perfusion magnetic resonance imaging (MRI) for differentiating glioma from brain metastasis, assessing MRI protocols and parameters.
A computerised search of Ovid-MEDLINE and EMBASE databases was performed up to 3 October 2017, to find studies on the diagnostic performance of perfusion MRI for differentiating glioma from brain metastasis. Pooled summary estimates of sensitivity and specificity were obtained using hierarchical logistic regression modelling. We conducted meta-regression and subgroup analyses to explain the effects of the study heterogeneity.
Eighteen studies with 900 patients were included. The pooled sensitivity and specificity were 90% (95% CI, 84–94%) and 91% (95% CI, 84–95%), respectively. The area under the hierarchical summary receiver operating characteristic curve was 0.96 (95% CI, 0.94–0.98). The meta-regression showed that the percentage of glioma in the study population and the study design were significant factors affecting study heterogeneity. In a subgroup analysis including patients with glioblastoma only, the pooled sensitivity was 92% (95% CI, 84–97%) and the pooled specificity was 94% (95% CI, 85–98%).
Although various perfusion MRI techniques were used, the current evidence supports the use of perfusion MRI to differentiate glioma from brain metastasis. In particular, perfusion MRI showed excellent diagnostic performance for differentiating glioblastoma from brain metastasis.
• Perfusion MRI shows high diagnostic performance for differentiating glioma from brain metastasis.
• The pooled sensitivity was 90% and pooled specificity was 91%.
• Peritumoral rCBV derived from DSC is a relatively well-validated.
KeywordsGlioblastoma Glioma Metastasis Magnetic resonance imaging Perfusion
Arterial spin labelling
Area under the receiver operating characteristic curve
Dynamic contrast-enhanced imaging
Dynamic susceptibility-weighted contrast-enhanced imaging
Hierarchical summary receiver operating characteristic
Initial area under the curve
Quality assessment of diagnostic accuracy studies-2
Relative cerebral blood flow
Relative cerebral blood volume
Compliance with ethical standards
The scientific guarantor of this publication is Ho Sung Kim.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors (Chong Hyun Suh) has significant statistical expertise (4 years of experience in a systematic review and meta-analysis).
Written informed consent was not required for this study because of the nature of our study, which was a systemic review and meta-analysis.
Institutional Review Board approval was not required because of the nature of our study, which was a systemic review and meta-analysis.
• A systemic review and meta-analysis performed at one institution
- 9.Cha S, Lupo JM, Chen MH et al (2007) Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 28:1078–1084CrossRefPubMedGoogle Scholar
- 11.Ganbold M, Harada M, Khashbat D, Abe T, Kageji T, Nagahiro S (2017) Differences in high-intensity signal volume between arterial spin labeling and contrast-enhanced T1-weighted imaging may be useful for differentiating glioblastoma from brain metastasis. J Med Invest 64:58–63CrossRefPubMedGoogle Scholar
- 14.Ma JH, Kim HS, Rim NJ, Kim SH, Cho KG (2010) Differentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions. AJNR Am J Neuroradiol 31:1699–1706CrossRefPubMedGoogle Scholar
- 16.Server A, Orheim TE, Graff BA, Josefsen R, Kumar T, Nakstad PH (2011) Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis. Neuroradiology 53:319–330CrossRefPubMedGoogle Scholar
- 17.Sparacia G, Gadde JA, Iaia A, Sparacia B, Midiri M (2016) Usefulness of quantitative peritumoural perfusion and proton spectroscopic magnetic resonance imaging evaluation in differentiating brain gliomas from solitary brain metastases. Neuroradiol J 29:160–167CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Higgins J, Green S Cochrane handbook for systematic reviews of interventions, version 5.1.0. The Cochrane Collaboration. http:// handbook.cochrane.org/chapter_9/9_5_2_ identifying_and_measuring_heterogeneity. htm. Updated March 2011. Accessed 2 October 2017
- 36.Bendini M, Marton E, Feletti A et al (2011) Primary and metastatic intraaxial brain tumors: prospective comparison of multivoxel 2D chemical-shift imaging (CSI) proton MR spectroscopy, perfusion MRI, and histopathological findings in a group of 159 patients. Acta Neurochir 153:403–412CrossRefPubMedGoogle Scholar
- 54.Huang J, Wang AM, Shetty A et al (2011) Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling. Magn Reson Imaging 29:993–1001CrossRefPubMedGoogle Scholar
- 55.Jakubovic R, Sahgal A, Ruschin M, Pejovic-Milic A, Milwid R, Aviv RI (2014) Non tumor perfusion changes following stereotactic radiosurgery to brain metastases. Technol Cancer Res TreatGoogle Scholar
- 58.Kapadia A, Mehrabian H, Conklin J et al (2017) Temporal evolution of perfusion parameters in brain metastases treated with stereotactic radiosurgery: comparison of intravoxel incoherent motion and dynamic contrast enhanced MRI. J NeurooncolGoogle Scholar
- 68.Tsuchiya K, Aoki S, Shimoji K, Mori H, Kunimatsu A (2013) Consecutive acquisition of time-resolved contrast-enhanced MR angiography and perfusion MR imaging with added dose of gadolinium-based contrast agent aids diagnosis of suspected brain metastasis. Magn Reson Med Sci 12:87–93CrossRefPubMedGoogle Scholar
- 75.Park SM, Kim HS, Jahng GH, Ryu CW, Kim SY (2010) Combination of high-resolution susceptibility-weighted imaging and the apparent diffusion coefficient: added value to brain tumour imaging and clinical feasibility of non-contrast MRI at 3 T. Br J Radiol 83:466–475CrossRefPubMedPubMedCentralGoogle Scholar
- 76.Perfusion, Diffusion and Flow-MRI Biomarker Committee of the Quantitative Imaging Biomarkers Alliance (QIBA). Available at: http://qibawiki.rsna.org/index.php/Perfusion,_Diffusion_and_Flow-MRI_Biomarker_Ctte.